Ascentage Reports the US FDA’s Acceptance of IND Application for APG-5918 to Treat Solid Tumors and Hematologic Malignancies
- The US FDA has accepted the IND application of APG-5918, an oral EED protein inhibitor for the treatment of solid tumors & hematologic malignancies
- The FIH, multicenter, open-label P-I study evaluates the safety, tolerability & will determine the DLT, MTD along with the RP2D of APG-5918. The preclinical data of APG-5918 showed potent binding activity with EED protein, in vitro antiproliferative & in vivo antitumor activity
- EED protein stimulates the methyltransferase activity of EZH2 (highly expressed in tumor cells) therefore APG-5918 is used as an EED protein inhibitor to act against EZH2 & also can overcome tumor resistance along with delivering complete/durable tumor
Ref: PR Newswire | Image: Ascentage
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].